Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 19 2 2025 04 20 101 108 EN Nasrin Namdari Department of Hematology and Medical Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran Sezaneh Haghpanah Department of Hematology and Medical Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran Elahe Ataie Department of Hematology and Medical Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran Fateme Ghanbarian Department of Hematology and Medical Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran Maral Mokhtari Department of Hematology and Medical Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran Mahya Amini Department of Hematology and Medical Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran 2024 08 29 2025 04 06  Background: Acute-phase reactant proteins, particularly C-reactive protein (CRP), play a critical role in the initiation, progression, and recurrence of cancers such as acute myeloid leukemia. Materials and Methods: We retrospectively analyzed 127 newly diagnosed non-M3 acute myeloblastic leukemia (non-M3 AML) patients. We investigated pre-treatment levels of C-reactive protein (CRP), Albumin, and C-reactive protein to albumin ratio (CAR) with cytogenetics, response to induction therapy, recurrence, and overall survival. Results: We did not find any relationship between levels of CRP, Albumin, and C-reactive protein to albumin ratio (CAR) with complete remission rate, recurrence, and risk categorization of patients (P > 0.05). 3-and 5- year overall survival was 40.8% (with a standard error of 4.7%) and 30.1% (standard error: 5.3%), respectively. In addition, 3-year and 5-year event-free survival was 31.3% (standard error = 4.4%) and 25.8% (standard error = 4.8%), respectively. The only prognostic factor was allogenic stem cell transplantation (SCT). Conclusion: Although CRP, Albumin, and CAR serve as convenient prognostic markers, they were not predictive of overall survival (OS) and event-free survival (EFS) in AML patients. Further studies are needed in the future to confirm or refute our results.   https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/2315 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/2315/1075